DiaGenic

The Norwegian molecular diagnostics firm will use the funds to support its new strategy focused on neuroscience-related tests.

DiaGenic has developed quantitative real-time PCR-based blood tests for Alzheimer's disease and breast cancer, but will refocus its business primarily on its neuroscience-related molecular tests as opposed to its oncology tests, a company executive said.

News from TATAA Biocenter's European qPCR symposium in Göteborg, Sweden, included DiaGenic's PCR-based blood test for Alzheimer's disease and breast cancer; an 'ultrafast, ultracheap' portable real-time PCR system from KIST-Europe; high-resolution melting startup Epilabs from the University of Aarhus and Peter MacCallum Cancer Centre; and Helixis' new thermal cycler.

Myconostica's MycAssay Pneumocystis assay, DiaGenic's ADtect

The Spanish firm will distribute DiaGenic's Alzheimer's test in Europe and Latin America.

DiaGenic licensed biomarkers for mild cognitive impairment to drug firm Merz Pharmaceuticals, which will use the biomarkers for recruiting patients for Alzheimer's disease drug trials.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.